vimarsana.com

Page 4 - மரப்பட்டைகள் புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER

Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER April 20, 2021 GMT Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu ® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies. In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for approximately 12,000 deaths per year. 1 There are an estimated 35,000 people living with metastatic breast

Letters: Masking the Queen will be the crowning act of Covid heartlessness

Locals know how best to run national parks The church of St Michael de Rupe at Brentor in Dartmoor National Park, Devon Credit: russgallery images SIR – Seventy years ago, the first English national parks were set up. The Government recently said that they represented one of the most outstanding environmental achievements of the past 100 years. Since 1995, the national park authorities have been independent statutory bodies, with a majority of local councillors on their boards. However, according to documents leaked to the BBC’s Countryfile programme (shown March 28), the Government now plans to bring all the functions and responsibilities of the protected landscapes into a single organisational structure, effectively a new national quango.

Cross-national study associates low vitamin D levels with higher COVID-19-related mortality

Cross-national study associates low vitamin D levels with higher COVID-19-related mortality The coronavirus disease 2109 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Since SARS-CoV-2 was first detected in Wuhan, China, in December 2019, more than 120 million cases of COVID-19 have been confirmed. It has been reported that vitamin D supplementation can help reduce the fatal effects of COVID-19. Past studies have also tied vitamin D deficiency to increased mortality due to COVID-19. A new study by an international team of researchers – from New York University, Abu Dhabi, the Ludwig-Maximilians-Universität, München, and Barts Cancer Institute, London – showed that there are lower COVID-19 mortality rates in countries with the most insufficient annual sun exposure, but highest mean 25-hydroxyvitamin D (25(OH)D) or vitamin D (25)-HD levels.

Researchers develop virus-based treatment platform to fight pancreatic cancer

 E-Mail Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer. By using the virus in combination with other drugs, the treatment significantly extended survival in preclinical models of pancreatic cancer. Viruses that can selectively infect and destroy cancer cells, known as oncolytic viruses, are a promising new class of therapeutics for cancer. Through various mechanisms, oncolytic viruses kill cancer cells and elicit strong anti-tumour immune responses. However, current oncolytic virotherapy is unable to produce a long-term cure in patients, and the treatment has to be delivered directly into the tumour - a route that is not feasible for deeply embedded tumours, or tumours that have spread around the body.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.